Skip to main navigation

Live - Top Menu

  • Clinical Trials
  • Investors & Media
  • Careers
  • Contact Us
Menu
Close

Main navigation

  • Our Focus
  • Our Research
  • Our Medicine
  • Our Story
Home > Investors & Media > Press Releases
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Press Releases

Press Releases

Oct 31, 2022
Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis demonstrating improvement in outcomes, including transplant-free survival, for PBC patients treated with
Read More
Oct 25, 2022
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
MORRISTOWN, N.J. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial
Read More
Oct 12, 2022
Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022
MORRISTOWN, N.J. , Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and
Read More
Sep 30, 2022
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J. , Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
Read More
Sep 21, 2022
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- Intercept
Read More
Sep 20, 2022
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to natural history data from the Global PBC and UK -PBC patient registries MORRISTOWN, N.J. , Sept.
Read More
Sep 07, 2022
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
MORRISTOWN, N.J. , Sept. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and
Read More
Aug 29, 2022
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
MORRISTOWN, N.J. , Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in
Read More
Aug 19, 2022
Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
MORRISTOWN, N.J. , Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered
Read More
Aug 18, 2022
Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
MORRISTOWN, N.J. , Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the management team of
Read More

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Live - Footer Menu

  • Privacy Policy
  • Privacy Shield Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
305 Madison Avenue|Morristown, NJ 07960|T: 844-782-ICPT
© 2023 Intercept Pharmaceuticals, Inc.